Affiliation: Scripps Clinic
- Metabolic syndrome treatment strategiesKen Fujioka
Nutrition and Metabolism Research Center, Scripps Clinic Del Mar, San Diego, California 92130, USA
Pharmacotherapy 26:222S-226S. 2006..In addition, two drugs-sibutramine and rimonabant-have been evaluated and produced promising outcomes in the overall management of high-risk patients with metabolic syndrome...
- Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitusK Fujioka
Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, CA 92130, USA
Diabetes Obes Metab 2:175-87. 2000..To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent...
- Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical optionsKen Fujioka
Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, California 92130, USA
Obes Res 10:116S-123S. 2002..Several other drugs currently approved for other uses show promise in their ability to cause weight loss. Surgical options should be reserved for severely obese patients with significant medical comorbidities or physical conditions...
- Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulationKen Fujioka
Nutrition and Metabolic Research Center, Scripps Clinic Del Mar, San Diego, California 92310, USA
Clin Ther 25:515-29. 2003..This newer formulation may enhance patient compliance with oral therapy and improve long-term control of diabetes compared with the conventional immediate-release formulation of metformin (MIR)...
- Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-cK Fujioka
Department of Endocrinology, Scripps Clinic, La Jolla, San Diego, CA 92130, USA
Diabetes Obes Metab 7:28-39. 2005..Protocol 1 provided an evaluation of metformin XR at a commonly used dosage. Protocol 2 evaluated different dosages of metformin XR...
- Pharmacologic treatment options for obesity: current and potential medicationsKen Fujioka
Center for Weight Management, Scripps Clinic, San Diego, CA 92130, USA
Nutr Clin Pract 22:50-4. 2007..Currently available therapies are safe when used appropriately. New treatments with novel mechanisms of action are likely to be available in the future...
- The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndromeKen Fujioka
Division of Endocrinology, Department of Nutrition and Metabolic Research, Scripps Clinic, La Jolla, California 92130, USA
J Med Food 9:49-54. 2006..Insulin resistance was improved with fresh grapefruit. Although the mechanism of this weight loss is unknown it would appear reasonable to include grapefruit in a weight reduction diet...
- Obesity epidemic: what treatments work and whom do you treat?Ken Fujioka
Nutrition and Metabolic Research, Scripps Clinic, San Diego, Calif, USA
Manag Care 15:21-4. 2006
- Evaluating preoperative weight loss, binge eating disorder, and sexual abuse history on Roux-en-Y gastric bypass outcomeKen Fujioka
Department of Nutrition and Metabolic Research Center, Scripps Green Clinic, La Jolla, California, USA
Surg Obes Relat Dis 4:137-43. 2008..We examined preoperative weight loss, binge eating disorder (BED), and sexual abuse history and the interactions of these predictors to determine whether a cautionary approach to Roux-en-Y gastric bypass is warranted...
- Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunctionKen Fujioka
Center for Weight Management, Scripps Clinic, Department of Endocrinology and Diabetes, San Diego, CA, USA
JAAPA . 2007..Both classes of agent have shown promise, with potential not only to normalize fasting and postprandial glucose levels but also to improve beta-cell functioning and mass...
- Naltrexone for the treatment of obesity: review and updateMichael William Lee
Scripps Clinic Center for Weight Management, 12395 El Camino Real, Suite 317, San Diego, CA 92130, USA
Expert Opin Pharmacother 10:1841-5. 2009..While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion...
- Follow-up of nutritional and metabolic problems after bariatric surgeryKen Fujioka
Director of Nutrition and Metabolic Research, Scripps Clinic, Suite 317, 12395 El Camino Real, San Diego, CA 92130, USA
Diabetes Care 28:481-4. 2005..At the end of this report, a short section will be devoted to the problems associated with the malabsorptive procedures...
- Effects of sibutramine treatment in obese adolescents: a randomized trialRobert I Berkowitz
The Behavioral Health Center, The Children s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Ann Intern Med 145:81-90. 2006..Increased prevalence of adolescent obesity requires effective treatment options beyond behavior therapy...
- Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation studyLouis Aronne
Weill Cornell Medical College, New York, NY 10021, USA
J Clin Endocrinol Metab 92:2977-83. 2007..In previous 1-yr trials, treatment with pramlintide (120 microg), an analog of the beta-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes...
- Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trialJames W Anderson
Department of Internal Medicine, Veterans Affairs Medical Center, University of Kentucky, Lexington, Kentucky, USA
Obes Res 10:633-41. 2002..To critically examine the efficacy of bupropion SR for weight loss...
- Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu
Merck and Co, Inc, 126 E Lincoln Avenue, Rahway, New Jersey 07065
Cell Metab 4:275-82. 2006..These observations provide the first clinical insight into the human NPY-energy homeostatic pathway and suggest that solely targeting the NPY5R in future drug development programs is unlikely to produce therapeutic efficacy...